Company Research Report: Shorla Oncology
1. Company Overview
1.1 Name and Mission
- Company Name: Shorla Oncology
- Mission: To develop and commercialize innovative oncology drugs, focusing on indications where existing treatments are limited, in shortage, or inadequate for the target population. Shorla Oncology aims to improve patients' lives through science and innovation by rethinking, reimagining, and improving existing oncology treatments.
1.2 Founding Details
- Founding: Shorla Oncology was founded by Sharon Cunningham and Orlaith Ryan.
- Founders' Background:
- Sharon Cunningham: Over 14 years in leadership roles in the pharmaceutical industry with significant experience in finance and compliance. She holds various academic and professional credentials in finance and healthcare innovation.
- Orlaith Ryan: Over 14 years in the pharmaceutical industry with expertise in Analytical, QA, and Regulatory Affairs. Extensive experience with FDA and EMA.
1.3 Key People
- Sharon Cunningham: Co-founder & CEO
- Orlaith Ryan: Co-founder & CTO
- Rayna Herman: Chief Commercial Officer
1.4 Headquarters
- Ireland HQ: Questum Acceleration Center, Ballingarrane Science & Technology Park, Clonmel, Co. Tipperary, E91 V329, Ireland
- US Office: 245 Main St., 2nd Floor, Cambridge, MA 02142, USA
1.5 Employees
- Number of Employees: No information is available.
1.6 Revenue
- Revenue: No information is available.
1.7 Known For
- Shorla Oncology is known for developing innovative oncology treatments that address drug shortages and the needs of underserved populations.
2. Products
2.1 Product List
- JYLAMVO: Methotrexate for oncology and autoimmune diseases.
- NELARABINE INJECTION: No detailed information is provided.
- Pipeline Products:
- SH-105 (Tepylute): IV treatment for breast and ovarian cancer.
- SH-110: Oral liquid for glioma.
- SH-201: Liquid formulation for chronic myeloid leukemia, acute lymphoblastic leukemia, MDS, gastrointestinal tumors.
2.2 Product Descriptions
- JYLAMVO: An oncology and autoimmune drug with expanded FDA approval for pediatric indications.
- Tepylute (formerly SH-105): Recently approved by the FDA, intended to benefit women with breast and ovarian cancer.
- SH-110: Targets glioma patients with a focus on reducing treatment burden; it provides a palatable age-appropriate treatment.
- SH-201: First palatable oral liquid chemotherapeutic agent accepted by the FDA, targeting specific forms of leukemia and other cancers.
2.3 Key Features of Products
- JYLAMVO: Expanded FDA approval signifies its effectiveness and safety in pediatric indications.
- Tepylute (SH-105): Innovative formulation designed to meet the needs of breast and ovarian cancer patients, signifying a milestone in oncology treatments.
- SH-110: Focuses on improved delivery and acceptability for brain cancer treatment.
- SH-201: Unique oral liquid form enhances patient compliance and broadens treatment options for leukemia.
3. Recent Developments
3.1 Major Developments
- FDA Approvals:
- Tepylute: Approved for breast and ovarian cancer treatment.
- JYLAMVO™: Received FDA expanded approval for pediatric oncology and autoimmune indications.
3.2 New Features and Products
- Tepylute: Novel formulation introduced to the market.
- SH-110: Completed pre-IND meeting with significant benefits projected for brain cancer patients.
- SH-201: Gained FDA acceptance for NDA filing as a first palatable oral liquid treatment.
3.3 Partnerships and Accolades
- EY Entrepreneur Of The Year Finalists: Sharon Cunningham and Orlaith Ryan recognized as 2024 finalists.
- Participation in Health and Innovation Events: Active presence at events like Frontiers Health 2024 and CPHI Milan.
This report draws from publicly available data; as such, any sensitive or proprietary company information was not included in this analysis.
